Jonathan Jager

Jonathan Jaeger, PhD, is a data and statistical innovation expert. Jonathan is responsible for overseeing the development of data continuum solutions to facilitate quantitative based drug development decision making. Mr. Jaeger is a doctor in Statistics with a deep understanding of data and statistical challenges within clinical development and operations, particularly in the field of cell and gene therapies (Breyanzi®, ABECMA®)

Prior supporting Ubuntu Research, Mr. Jaeger had held various role including being in academic research (Université Catholique de Louvain, Belgium), statistician at Nestlé (Switzerland), Celgene (Switzerland), and Debiopharm (Switzerland), and most recently as the head of biometrics at Tigen (Switzerland). In addition, Mr. Jaeger has contributed to several stand alone projects as an independent statistical sciences consultant, in support of data-first generating biotechs.

LinkedIn profile : https://www.linkedin.com/in/jonathanjaeger/

Elizabeth Woodson

Elizabeth is an Executive Director with 20 years of experience in asset and program management, focused on the development and execution of strategic initiatives across functions. She has a track record of delivering on objectives while improving processes and controlling costs.

During her years in academia, CRO and biotech, Elizabeth has supported the evaluation of peptide-based and autologous vaccines, monoclonal antibodies, biosimilars, oncolytic virus and small molecules, as well as the initial approval or label expansion of YERVOY®, Prevnar13®, and Latuda®.

Elizabeth earned her MS in Health Evaluation Sciences from the University of Virginia (USA).
Elizabeth joined Ubuntu because the energy of a team collaborating to bring new medicines to the clinic is unmatched.

LinkedIn profile : https://www.linkedin.com/in/elizabeth-woodson-2b122a11/

Shelley Sly

Shelley heads the Center Engagement and Relationship capabilities at Ubuntu, distilling her 25+ years of clinical research experience in crafting this unique biotech-oriented functionality. As an accomplished Clinical Operations Professional across the pharmaceutical, biotechnology and CRO industries, she is recognized for her talents in building and leading high- performing global clinical operations teams, her unique abilities in forging deep and enduring partnerships with leading industry KOLs and their research teams, and her dedicated & unwavering passion to bringing innovative therapies to patients. Shelley's passion for collaboration and her exceptional interpersonal skills enables her to foster productive relationships that drive clinical trial innovation and accelerate development of life-changing treatments.

Shelley has experience in cell and gene therapies and has contributed to the development of products such as Obe-cel, AUTO3 and AUTO4.
Shelley has earned her BS in Biochemistry from New York.
Shelley joined Ubuntu because she is passionately dedicated to the mission of bringing innovative therapies to patients in an efficient and effective way.

LinkedIn profile : https://www.linkedin.com/in/shelley-sly-aa92865/

Dr. Philippe Pultar, MD

Philippe is a French-trained physician and pharmaceutical executive with more than two decades of experience, in both large pharmaceutical companies (Novartis, Eli Lilly) and innovative biotechs (ImClone Systems, Zentalis).
He has extensive experience in early and late-stage Clinical Development and Medical Affairs focusing in oncology. He contributed to the development of various compounds such as Azenosertib, Isturisa® (osilodrostat), Signifor® (pasireotide), Odomzo® (sonidegib), Tabreca® (capmatinib), Rixathon® (rituximab), Portrazza™ (necitumumab), Erbitux® (cetuximab).

Adept at leveraging pre-clinical and clinical data to design and implement clinical development plans, building partnerships with internal and external stakeholders.
His versatile skill set allows him to seamlessly transition from a strategic overview of a drug development plan to hands-on operational details, all with a relentless focus on ensuring that every facet of a project aligns with the overarching business objectives.
Philippie obtained his medical degree from the Université de Médecine de Poitiers, France.

Phillipe is excited to join Ubuntu because of its clear mission to rapidly deliver innovative therapies to patients through strategic partnerships with emerging biotech organizations, and its unique platform, Dimension-T™, dedicated to optimizing the drug development process for more meaningful patient outcomes.

LinkedIn profile : http://www.linkedin.com/in/pultar

Him/He/His

He is a highly experienced clinical research professional with a career spanning 23 years in managing strategic & operational global leadership roles of increasing responsibilities and complexities. Over the past 17 years, these jobs profiles involved establishing and growing regional and global business units/functions across all domains of development operations. Worked for global biopharmaceutical and clinical research organizations in driving the operations and business aspects across phase I to IV trials including strategy development, operational excellence, change management, stakeholder management, and building high performing teams.

He has earned his B.S in pharmaceutical sciences from Mumbai university, post graduation in clinical research from Mumbai and MBA from NMIMS, Mumbai.

He joined Ubuntu as it inspires him to think differently and offers the opportunity to lead from the heart in making difference in people's lives.

Jeffrey Scott Yablon

Mr. Jeffrey Scott Yablon is an executive consultant to the growing Ubuntu team. With a BA from Stockton University and an EMBA from Fairleigh Dickinson University, Jeff will lead the Business Development initiatives for Ubuntu Research Inc., establishing strategic customer relationships and guiding the adoption of Ubuntu’s DIMENSION-T product across market segments.

Jeff is a seasoned life science executive and US Army veteran, serving as a Captain in the Army. With 30 years of experience in the pharmaceutical & med-tech industry, Jeff’s core competencies include clinical operations/ management, investor relations, clinical technologies, and laboratory sciences. His expertise in enterprise planning, business development, and international business leadership are amongst many of the leadership assets that Jeff brings to the Ubuntu executive team.

Jeff is currently an advisor at Cogmotos Inc., a biopharmaceutical company, overseeing investor outreach and operational management. Previously, he held prominent positions such as Senior VP at Frontage Laboratories, President/CEO at Jigsaw Clinical Research Solutions, and VP/GM at InClinica Inc. Jeff has led engagements in pharmaceutical development and has global operations management experience from top companies like Abbott Laboratories, Parexel, ICON Labs and several others over his illustrious career. Jeff has further contributed to the scientific community through teaching appointments and board advisory at various universities in the US and received recognition for his contributions to the clinical research ecosystem across Asia-Pacific.

Jeff shares, "I joined the Ubuntu team to facilitate positive change in the way clinical development is managed and conducted. The Ubuntu Dimension-T platform is a set of tools that can increase operating efficiency and reduce costs and furthermore accelerate time to market for needed biopharmaceutical products."